Cardiovascular Systems, Inc. to Participate at Three September Investor Conferences

ST. PAUL, Minn.--()--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management will participate and host investor meetings at the following three conferences:

4th Annual Dougherty & Company Institutional Investor Conference
Millennium Hotel
Minneapolis, Minn.
Thursday, September 5, 2019

Morgan Stanley 17th Annual Global Healthcare Conference
Grand Hyatt
New York, NY
Wednesday, September 11, 2019

Lake Street Capital Markets 3rd Annual Best Ideas Growth Conference
Parker New York
New York, NY
Thursday, September 12, 2019

You may access the live audio webcast of the Morgan Stanley presentation at 2:10 p.m. ET on Wednesday, September 11, 2019, or a replay of the event, on the company’s investor relations website, https://investors.csi360.com/events-and-presentations/events-calendar/default.aspx.

About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s OAS treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in peripheral arteries in August 2007. In October 2013, the company received FDA approval for the use of the Diamondback Orbital Atherectomy System in coronary arteries. The Stealth 360® Peripheral Orbital Atherectomy System (OAS) received CE Mark in October 2014. In March 2017, the company received PMDA approval in Japan for the Diamondback 360® Coronary OAS Micro Crown and reimbursement approval effective February 2018. Over 470,000 of CSI’s devices have been sold to leading institutions worldwide. For more information, visit the company’s website at www.csi360.com.

Contacts

Cardiovascular Systems, Inc.
Jack Nielsen
(651) 202-4919
j.nielsen@csi360.com

Padilla
Matt Sullivan
(612) 455-1709
matt.sullivan@padillaco.com

Contacts

Cardiovascular Systems, Inc.
Jack Nielsen
(651) 202-4919
j.nielsen@csi360.com

Padilla
Matt Sullivan
(612) 455-1709
matt.sullivan@padillaco.com